A compound comprising: a modified oligonucleotide consisting of 10 to 20 linked nucleosides, wherein the modified oligonucleotide comprises: a 5'-wing consisting of 2 to 5 linked nucleosides; a 3'-wing consisting of 2 to 5 linked nucleosides; and a gap between the 5'-wing and the 3'-wing consisting of 6 to 14 linked 2'-deoxynucleosides; and wherein at least one of the 5'-wing and the 3'-wing comprises at least one bicyclic nucleoside; at least one of the 5'-wing and the 3'-wing comprises at least one 2'-substituted nucleoside; and at least one of the 5'-wing and the 3'-wing comprises at least one 2'-deoxynucleoside; wherein at least the sugar moieties of the nucleosides of the 3'-most nucleoside of the 5'-wing and the 5'-most nucleoside of the 3'-wing differ from the sugar moiety of the neighboring gap nucleosides; wherein the nucleobase sequence of the modified oligonucleotide is complementary to the nucleobase sequence of a target nucleic acid; and wherein the compound is an antisense compound capable of inhibiting expression of the target nucleic acid in a cell; with the proviso that the compound does not consist of the specific modified oligonucleotide with the structure: m C e A k m C e A k m C d A d G d T d A d G d A d T d G k A e G k G d G e, wherein, in the specific modified oligonucleotide structure, A is a nucleoside having an adenine nucleobase, T is a nucleoside having a thymine nucleobase, G is a nucleoside having a guanine nucleobase, and m C is a nucleoside having a 5-methylcytosine nucleobase; nucleotides followed by a subscript "e" indicate MOE subunits, wherein MOE is a nucleoside comprising a sugar comprising a -OCH 2 CH 2 OCH 3 group at the 2' position of the sugar ring; nucleotides followed by a subscript "k" indicate a 6 -CH 3 bicyclic nucleoside in the β-D configuration having a sugar moiety comprising a bridge connecting the 4'-carbon and the 2'-carbon, wherein the bridge has the formula: 4'-CH(CH 3)-O-2'; nucleotides followed by a subscript "d" indicate 2'-deoxynucleotides; and the internucleoside linkages throughout the specific modified oligonucleotide are phosphorothioate (P=S) linkages. a modified oligonucleotide consisting of 10 to 20 linked nucleosides, wherein the modified oligonucleotide comprises: a 5'-wing consisting of 2 to 5 linked nucleosides; a 3'-wing consisting of 2 to 5 linked nucleosides; and a gap between the 5'-wing and the 3'-wing consisting of 6 to 14 linked 2'-deoxynucleosides; and wherein at least one of the 5'-wing and the 3'-wing comprises at least one bicyclic nucleoside; at least one of the 5'-wing and the 3'-wing comprises at least one 2'-substituted nucleoside; and at least one of the 5'-wing and the 3'-wing comprises at least one 2'-deoxynucleoside; wherein at least the sugar moieties of the nucleosides of the 3'-most nucleoside of the 5'-wing and the 5'-most nucleoside of the 3'-wing differ from the sugar moiety of the neighboring gap nucleosides; wherein the nucleobase sequence of the modified oligonucleotide is complementary to the nucleobase sequence of a target nucleic acid; and wherein the compound is an antisense compound capable of inhibiting expression of the target nucleic acid in a cell; with the proviso that the compound does not consist of the specific modified oligonucleotide with the structure: m C e A k m C e A k m C d A d G d T d A d G d A d T d G k A e G k G d G e, wherein, in the specific modified oligonucleotide structure, A is a nucleoside having an adenine nucleobase, T is a nucleoside having a thymine nucleobase, G is a nucleoside having a guanine nucleobase, and m C is a nucleoside having a 5-methylcytosine nucleobase; nucleotides followed by a subscript "e" indicate MOE subunits, wherein MOE is a nucleoside comprising a sugar comprising a -OCH 2 CH 2 OCH 3 group at the 2' position of the sugar ring; nucleotides followed by a subscript "k" indicate a 6 -CH 3 bicyclic nucleoside in the β-D configuration having a sugar moiety comprising a bridge connecting the 4'-carbon and the 2'-carbon, wherein the bridge has the formula: 4'-CH(CH 3)-O-2'; nucleotides followed by a subscript "d" indicate 2'-deoxynucleotides; and the internucleoside linkages throughout the specific modified oligonucleotide are phosphorothioate (P=S) linkages.